Agathangelidis Andreas, Rosenquist Richard, Davi Frederic, Ghia Paolo, Belessi Chrysoula, Hadzidimitriou Anastasia, Stamatopoulos Kostas
Institute of Applied Biosciences, Center for Research and Technology, Thessaloniki, Greece.
Department of Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden.
Methods Mol Biol. 2019;1881:51-62. doi: 10.1007/978-1-4939-8876-1_5.
The formation of B-cell receptor immunoglobulin (BcR IG) is the result of a multi-step process that starts at the pro-B cell stage with the VDJ gene recombination of IG genes of the heavy chain, followed by VJ recombination of the light chain genes at the pre-B II cell stage. As a result, a fully functional BcR IG is expressed on the surface of any given naive B cell. After antigen encounter, somatic hypermutation (SHM) and class-switch recombination (CSR) act on the rearranged IG genes within the context of affinity maturation, leading to the expression of a BcR IG with unique immunogenetic and functional characteristics. Since B-cell neoplasms arise from the transformation of a single B cell, this renders IG gene rearrangements ideal clonal markers as they will be identical in all neoplastic cells of each individual clone. Furthermore, the rearranged IG sequence can also serve as a cell development/maturation marker, given that its configuration is tightly linked to specific B-cell developmental stages. Finally, in certain instances, as in the case of chronic lymphocytic leukemia (CLL), the clonotypic IG sequence and, more specifically, the load of somatic hypermutations within the rearranged IG heavy variable (IGHV) gene, holds prognostic and potentially predictive value. However, in order to take full advantage of the information provided from the analysis of the clonotypic IG gene rearrangement sequences, robust methods and tools need to be applied. Here, we provide details regarding the methodologies necessary to ensure reliable IG sequence analysis based on the recognized expertise of the European Research initiative on CLL (ERIC). All methodological and analytical steps are described below, starting from the isolation of blood mononuclear cells (PBMC), moving to the identification of the clonotypic IG rearrangement and ending with the accurate interpretation of the SHM status.
B细胞受体免疫球蛋白(BcR IG)的形成是一个多步骤过程的结果,该过程始于前B细胞阶段,重链IG基因进行V(D)J基因重组,随后在前B II细胞阶段轻链基因进行VJ重组。因此,任何给定的初始B细胞表面都会表达一个功能完整的BcR IG。抗原接触后,体细胞高频突变(SHM)和类别转换重组(CSR)在亲和力成熟的背景下作用于重排的IG基因,导致具有独特免疫遗传和功能特征的BcR IG表达。由于B细胞肿瘤起源于单个B细胞的转化,这使得IG基因重排成为理想的克隆标志物,因为它们在每个个体克隆的所有肿瘤细胞中都是相同的。此外,重排的IG序列也可以作为细胞发育/成熟的标志物,因为其构型与特定B细胞发育阶段紧密相关。最后,在某些情况下,如慢性淋巴细胞白血病(CLL),克隆型IG序列,更具体地说,重排的IG重链可变区(IGHV)基因中的体细胞高频突变负荷,具有预后和潜在的预测价值。然而,为了充分利用克隆型IG基因重排序列分析提供的信息,需要应用强大的方法和工具。在此,我们根据欧洲慢性淋巴细胞白血病研究倡议(ERIC)的公认专业知识,提供有关确保可靠IG序列分析所需方法的详细信息。所有方法和分析步骤如下所述,从血液单核细胞(PBMC)的分离开始,到克隆型IG重排的鉴定,最后到SHM状态的准确解读。